Skip to content
Evigrade
ModerateVitamin K antagonist anticoagulants×HMG-CoA reductase inhibitors (statins)

Updated · Methodology

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist. The Spanish acenocoumarol SmPCs, both the originator and a generic, list atorvastatin among statins that can potentiate its anticoagulant effect (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The documents do not say how atorvastatin produces this effect (AEMPS). The figures in the atorvastatin SmPC come from warfarin. In patients on long-term warfarin, atorvastatin 80 mg a day slightly shortened the prothrombin time over the first 4 days, by about 1.7 seconds. The value returned to normal by day 15 (atorvastatin SmPC, AEMPS). Clinically significant interactions of atorvastatin with anticoagulants have been reported very rarely (atorvastatin SmPC, AEMPS). The US label describes the effect of atorvastatin on prothrombin time during long-term warfarin treatment as not clinically significant (atorvastatin prescribing information, US Food and Drug Administration, FDA).

Symptoms

If the effect of acenocoumarol increases, the main risk is bleeding (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol can cause serious or fatal bleeding, including haemorrhagic shock. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints, as well as fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain (acenocoumarol SmPC, AEMPS).

Management

No document contraindicates or prohibits this combination, but coagulation is monitored when atorvastatin is started. In people taking a coumarin anticoagulant, measure the prothrombin time before starting atorvastatin and frequently enough early in treatment to make sure there is no significant change. After that, check it at the intervals usual for the anticoagulant (atorvastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Repeat the same steps if the atorvastatin dose is changed or atorvastatin is stopped (atorvastatin SmPC, AEMPS). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week, both when atorvastatin is added and when it is stopped (acenocoumarol SmPCs, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt it and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol

Other interactions with Atorvastatin